Monjuvi (tafasitamab-cxix) / Xencor, Incyte, InnoCare, Knight Therap, Specialised Therap - LARVOL DELTA

PATTERNS OF INFECTION AND THEIR IMPACT ON THE OUTCOMES OF NEXT- GENERATION B-CELL DEPLETING IMMUNOTHERAPIES IN NON-HODGKIN'S LYMPHOMAS: FINDINGS FROM A MULTICENTER RETROSPECTIVE REAL-LIFE COHORT (SIE 2026) - "158 NHL pts received 195 immunotherapy lines: 108 CAR-T cells (58 Axi-cel, 33 Tisa-cel, 16 Brexu-cel, 1 Li- so-cel), 40 bispecific MoAbs (13 glofitamab, 18 epcoritamab, 9 mosunetuzumab), 26 ADCs (11 anti-CD19 ADC: loncastux- imab, 15 anti-CD79b ADC Polatuzumab with rituximab-ben- damustine), and 21 naked MoAbs (tafasitamab-lenalido- mide). Infections are common in novel immunothera- py for NHL; however, most cases occurred early (<100 days) and were mild-to-moderate and manageable. In R/R NHL pts, the main cause of death remains lymphoma pro- gression."

Retrospective data • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • CD79B

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Brown University

New P2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • BCL2 • IRF4

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Brown University | Initiation date: May 2026 ➔ Nov 2026

Trial initiation date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • BCL2 • IRF4

A tale of two triplets: tafasitamab, rituximab, lenalidomide and epcoritamab, rituximab, lenalidomide in relapsed/refractory follicular lymphoma. (PubMed, Expert Opin Biol Ther) - No abstract available

Journal • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2026 ➔ Feb 2026

Enrollment open • Trial initiation date • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: M.D. Anderson Cancer Center

New P1/2 trial • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

CC-99282-NHL-001: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (clinicaltrials.gov) - P1/2 | N=387 | Recruiting | Sponsor: Celgene | Phase classification: P1 ➔ P1/2 | N=210 ➔ 387

Enrollment change • Phase classification • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

CC-99282-NHL-001: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: Celgene

New P1 trial • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

CC-99282-NHL-001: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (clinicaltrials.gov) - P1 | N=210 | Recruiting | Sponsor: Celgene | Trial completion date: May 2024 ➔ Dec 2025 | Trial primary completion date: Jun 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

CC-99282-NHL-001: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (clinicaltrials.gov) - P1 | N=205 | Recruiting | Sponsor: Celgene | N=100 ➔ 205

Enrollment change • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

CC-99282-NHL-001: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Celgene | Not yet recruiting ➔ Recruiting | Trial primary completion date: May 2024 ➔ Jun 2023

Enrollment open • Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (clinicaltrials.gov) - P1 | N=25 | Not yet recruiting | Sponsor: OHSU Knight Cancer Institute

New P1 trial • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • IGH

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (clinicaltrials.gov) - P1 | N=25 | Recruiting | Sponsor: OHSU Knight Cancer Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • IGH

CC-99282-NHL-001: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (clinicaltrials.gov) - P1/2 | N=348 | Recruiting | Sponsor: Celgene | Trial completion date: Dec 2025 ➔ Apr 2027 | Trial primary completion date: Dec 2024 ➔ Apr 2026

Trial completion date • Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

CC-99282-NHL-001: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (clinicaltrials.gov) - P1/2 | N=438 | Active, not recruiting | Sponsor: Celgene | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2027 ➔ Feb 2028 | Trial primary completion date: Apr 2026 ➔ Apr 2027

Enrollment closed • Trial completion date • Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: OHSU Knight Cancer Institute | Trial completion date: Jan 2027 ➔ Jan 2028 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • IGH

19-00153: A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma. (clinicaltrialsregister.eu) - P1/2 | N=64 | Recruiting | Sponsor: Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR | Active, not recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders (clinicaltrials.gov) - P1/2 | N=47 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting | Initiation date: Nov 2024 ➔ Jul 2024

Enrollment open • Trial initiation date • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders (clinicaltrials.gov) - P1/2 | N=47 | Not yet recruiting | Sponsor: M.D. Anderson Cancer Center

New P1/2 trial • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting | Initiation date: Oct 2021 ➔ Mar 2022

Enrollment open • Trial initiation date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study (clinicaltrials.gov) - P2 | N=62 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Recruiting ➔ Active, not recruiting

Enrollment closed • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Jan 2025 ➔ Jan 2027 | Trial primary completion date: Jan 2025 ➔ Jan 2027

Trial completion date • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

LONCASTUXIMAB TESIRINE: A NEW THERAPEUTICAL OPTION IN A HEAVILY PRETREATED ELDERLY PATIENT (SIE 2026) - "The re- sponse was poor, so he switched to a second line treatment with tafasitamab and lenalidomide (due to age and comor- bidities). Conclusions.The patient, even with the complications, was able to complete 10 cycles of loncastuximab tesirine, with a good quality of life and a PFS of 8.9 months (PFS of registra- tion study was 4,9 months). The case shows that the treat- ment with loncastuximab tesirine may represent a feasible option in elderly patients relapsed patients and shows differ- ent adverse effects that can come with the treatment."

Clinical • IO biomarker • Acute Kidney Injury • Atrial Fibrillation • B Cell Lymphoma • Cardiovascular • Diabetes • Diffuse Large B Cell Lymphoma • Geriatric Disorders • Hematological Malignancies • Lymphoma • Metabolic Disorders • Myocardial Infarction • Non-Hodgkin’s Lymphoma • Renal Disease • CD19

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma. (PubMed, J Hematol Oncol) - "This study identifies novel radiological risk factors for CD19-CAR failure in CNSL, namely pCE and LMD. Outcome in this setting is unfavorable and encouraging salvage treatments warrant prospective evaluation."

Journal • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

PRO-MIND: HEALTH-RELATED QUALITY OF LIFE AND OUTCOMES WITH TAFASITAMAB-LENALIDOMIDE IN PATIENTS WITH AUTOLOGOUS STEM CELL TRANSPLANTATION-INELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B- CELL LYMPHOMA (SIE 2026) - "In secondary domain-level analys- es, higher baseline physical functioning (HR 0.83, 95% CI 0.73, 0.95 per 10-point increase, p=0.005) and baseline fa- tigue (HR 1.27, 95% CI 1.12, 1.45 per 10-point increase, p<0.001) were strongly associated with PFS; other function- al/symptom domains were directionally consistent but had less pronounced associations.Validation in larger cohorts with multivariable adjustment and longer follow-up is need- ed. However, this preliminary analysis suggests that base- line global HRQoL may have prognostic associations with PFS."

Clinical • HEOR • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Transplantation